Stockwinners Market Radar for December 26, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Roche (RRHBY) announced that the U.S. Food and Drug Administration has granted Emergency Use Authorization for its COVID-19 At-Home Test. "The test uses a simple anterior nasal swab sample that can be conveniently self-collected and self-tested by individuals aged 14 years and older, and by an adult for children aged 2-13 years old. The test is able to produce accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron. [...] Starting in January, the COVID-19 At-Home Test will be available across the United States and in accordance with local guidelines and testing strategies. At the time of launch, Roche has the capacity to produce tens of millions of tests per month to help support the pandemic response. The COVID-19 At-Home Test offers a convenient frequent testing option without the need to visit a healthcare provider," the company stated. 2. According to Mastercard (MA) SpendingPulse, holiday retail sales excluding automotive increased 8.5% year-over-year this holiday season, running from November 1 through December 24. Notably, online sales grew 11.0% compared to the same period last year, the preliminary insights show. Mastercard SpendingPulse measures in-store and online retail sales across all forms of payment. 3. The Food and Drug Administration's authorization of Pfizer 's (PFE) COVID-19 pill Paxlovid on Wednesday, which represents an extraordinary coup for Pfizer, its second of the pandemic, Josh Nathan-Kazis wrote in this week's edition of Barron's. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher. Investors had been slow to buy into the revamped Pfizer. Since the start of November, however, Pfizer shares have exploded. And yet, the stock remains relatively cheap, trading at just 9.8-times earnings expected over the next 12 months, according to FactSet, the author added. 4. Sony (SONY) and Marvel's "Spider-Man: No Way Home" won the Christmas box office, grossing $81.5M from 4,336 locations in North America to finish Sunday with $467.3M domestically and over $1B worldwide. The movie also scored the third-best Christmas Day gross of all time in North America with $31.7M. 5. Ranpak (PACK) saw a positive mention in this week's edition of Barron's.

15:44 EST Southwest Gas confirms extension of Carl Icahn's unsolicited tender offer - Southwest Gas (SWX) has confirmed that an affiliate of Carl Icahn extended its tender offer to acquire any and all outstanding common shares of the Company for $75.00 per share in cash. As previously announced, Southwest Gas' Board of Directors rejected "Icahn's unsolicited, inadequate, structurally coercive, highly conditional and illusory tender offer. Accordingly, the Board continues to recommend that stockholders not tender any of their shares into the Offer," the company said. In a statement, Southwest Gas said that, "The Southwest Gas Board and management team are executing a clear and detailed strategy to create value and are committed to taking actions consistent with the focus of long-term stockholder value creation. The Board thoroughly reviewed Mr. Icahn's Offer, in consultation with our external financial and legal advisors, and unanimously determined that the Offer is inadequate and undervalues the Company, has no certainty of completion, and is not in the best interests of Southwest Gas stockholders. Tendering into Mr. Icahn's Offer would only encourage an opportunistic attempt to acquire Southwest Gas at an inadequate price and contingent upon a long list of ambiguous conditions, some of which Mr. Icahn has made no move to fulfill. Accordingly, the Board continues to recommend that stockholders not tender their shares into Mr. Icahn's unsolicited, inadequate, structurally coercive, highly conditional and illusory tender offer."

07:07 EST Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization - Roche announced that the U.S. Food and Drug Administration has granted Emergency Use Authorization for its COVID-19 At-Home Test. "The test uses a simple anterior nasal swab sample that can be conveniently self-collected and self-tested by individuals aged 14 years and older, and by an adult for children aged 2-13 years old. The test is able to produce accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron. The FDA's EUA decision stems from Roche's participation in the National Institutes of Health Rapid Acceleration of Diagnostics' Independent Test Assessment Program, which aims to accelerate the regulatory review and availability of high-quality, accurate and reliable OTC tests to the American public. The COVID-19 At-Home Test was prioritised by the FDA based on Roche and SD Biosensor's ability to deliver large quantities of high-quality tests and ramp up manufacturing to meet future demands. Starting in January, the COVID-19 At-Home Test will be available across the United States and in accordance with local guidelines and testing strategies. At the time of launch, Roche has the capacity to produce tens of millions of tests per month to help support the pandemic response. The COVID-19 At-Home Test offers a convenient frequent testing option without the need to visit a healthcare provider," the company stated.